Colorectal Cancer Clinical Trials in San Antonio

Showing 101-120 of 248 trials

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

NCT04616196

This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC) and colorectal carcinoma (CRC).

Head and Neck Squamous Cell CarcinomaColorectal Cancer

Nektar Therapeutics25 participantsStarted Oct 2020

San Diego, California, United States • San Francisco, California, United States • Minneapolis, Minnesota, United States +3 more locations

TERMINATEDPhase 2< 1 mile

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

NCT04952753

The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of mCRC. This study aims to explore whether different mechanisms of action may reverse resistance and improve responsiveness to the currently considered SOC anti-cancer therapy in the second line metastatic colorectal cancer (mCRC) setting.

Metastatic Colorectal Cancer

Novartis Pharmaceuticals204 participantsStarted Nov 2021

Los Angeles, California, United States • Ann Arbor, Michigan, United States • St Louis, Missouri, United States +52 more locations

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Colorectal Cancer Trials in Other Cities

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

ColoCare Study - Colorectal Cancer Cohort

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

Other Conditions in San Antonio